ArticleActa ortopedica brasileira2013
Immunohistochemical expression of vegf and her-2 proteins in osteosarcoma biopsies.
Article in Acta ortopedica brasileira, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- The role of vascular endothelial growth factor as a prognostic and clinicopathological marker in osteosarcoma: a systematic review and meta-analysis.Journal of orthopaedic surgery and research · 2021Pooled it
- Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma.Clinical and experimental medicine · 2016Pooled it
- HER-2 expression in biopsy and surgical specimen on prognosis of osteosarcoma: A systematic review and meta-analysis of 16 studies.Medicine · 2016Pooled it
- Introducing Fluorescence-Guided Surgery for Pediatric Ewing, Osteo-, and Rhabdomyosarcomas: A Literature Review.Biomedicines · 2021Review
- Investigating the Relationship between of Vascular Endothelial Growth Factor and HER-2neu in IHC Staining with Metastasis and Mortality in Patients with Osteosarcoma.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Caveolin-1 Expression Together with VEGF can be a Predictor for Lung Metastasis and Poor Prognosis in Osteosarcoma.Pathology oncology research : POR · 2020Article
- Expression ofTranslational cancer research · 2019Article
- shRNA-mediated silencing of hTERT suppresses proliferation and promotes apoptosis in osteosarcoma cells.Cancer gene therapy · 2017Article
- Expression profile of Twist, vascular endothelial growth factor and CD34 in patients with different phases of osteosarcoma.Oncology letters · 2015Article
- Comments on Liu Yet al. "Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies".Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Correlation between the expression of vegf and survival in osteosarcoma.Acta ortopedica brasileira · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo identify the prevalence of erbB-2 and vascular endothelial growth factor (VEGF) in osteosarcoma biopsies and to correlate them with possible prognosis factors.
methodsRetrospective study conducted at the Hospital do Câncer de Barretos-SP including 27 osteosarcoma biopsies immunohistochemically stained for VEGF and erbB-2. The pathological characteristics were collected from medical records of patients to correlate with markers.
resultsIn 27 biopsies, four overexpressed VEGF and three overexpressed erbB-2. Two thirds of patients had no metastases. Almost all patients with overexpression of VEGF showed metastases. Overexpression of erbB-2 was inversely related to the presence of metastases. There was no significant association between markers and prognosis.
conclusionWe identified a low prevalence of erbB-2 and VEGF in the sample. There was no significant association between overexpression of markers and pathological features. A larger sample and a longer follow-up, in addition to using new laboratory techniques can determine the real expression of VEGF and erbB-2 and its role in osteosarcoma . Level of Evidence III, Case-Control Study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.